Furthermore, the TGF-β pathway suppresses tumorigenesis in early-stage cancers, including breast cancer; therefore, a careful use of inhibitors is needed in order to suppress the tumorigenic arm of the pathway, while fostering the tumor-suppressive one (Shi et al., 2011; Smith et al., 2012). Here, TGFB1 is linked to neoplasm.